Current HIV/AIDS Reports

, Volume 15, Issue 2, pp 155–161 | Cite as

Treatment of Hepatitis C during Pregnancy-Weighing the Risks and Benefits in Contrast to HIV

  • A. Sidney BarrittIV
  • Ravi Jhaveri
Co-infections and Comorbidity (S Naggie, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Co-infections and Comorbidity


Purpose of Review

Increasing hepatitis C virus (HCV) cases over the past decade have raised concerns about subsequent increased cases in infants due to mother to child transmission (MTCT). Many are reminded of the early days of HIV and the rationale for using antiretroviral agents during pregnancy.

Recent Findings

Direct-acting antivirals (DAAs) that are highly potent, all-oral, short-duration regimens that cure HCV have led many to consider what it would entail to use DAAs for pregnant women. Considering HIV and Hepatitis B virus (HBV) as two infections with MTCT to draw lessons from, DAA use to interrupt HCV MTCT comes with risks, costs, and many potential benefits.


When considering how to effectively curb the current epidemic of HCV in the US population, using DAAs to treat pregnant women with HCV offers potential benefits to the mother immediately, to the pair in the short-term and to the child, family, and society over a lifetime.


Hepatitis C Pregnancy Mother to children transmission Vertical transmission 



Hepatitis C


Mother to children transmission


Directly acting antivirals


Sustained virologic response


Compliance with Ethical Standards

Conflict of Interest

A. Sidney Barritt IV declares no conflict of interest. Ravi Jhaveri received a grant from Merck and has participated in clinical trials with Gilead and Abbvie.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.


  1. 1.
    Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med. 2001;345(1):41–52. Scholar
  2. 2.
    Afdhal N, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014;370(20):1889–98. Scholar
  3. 3.
    Feld JJ, Kowdley KV, Coakley E, Sigal S, Nelson DR, Crawford D, et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014;370(17):1594–603. Scholar
  4. 4.
    Hezode C, Asselah T, Reddy KR, Hassanein T, Berenguer M, Fleischer-Stepniewska K, et al. Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial. Lancet. 2015;385:2502–9. Scholar
  5. 5.
    Sulkowski M, Hezode C, Gerstoft J, Vierling JM, Mallolas J, Pol S, et al. Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial. Lancet. 2015;385(9973):1087–97. Scholar
  6. 6.
    Balistreri WF, Murray KF, Rosenthal P, Bansal S, Lin CH, Kersey K, et al. The safety and effectiveness of ledipasvir-sofosbuvir in adolescents 12-17 years old with hepatitis C virus genotype 1 infection. Hepatology. 2017;66(2):371–8. Scholar
  7. 7.
    Forns X, Lee SS, Valdes J, Lens S, Ghalib R, Aguilar H, et al. Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial. Lancet Infect Dis. 2017;17:1062–8. Scholar
  8. 8.
    Kwo PY, Poordad F, Asatryan A, Wang S, Wyles DL, Hassanein T, et al. Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis. J Hepatol. 2017;67(2):263–71. Scholar
  9. 9.
    Pergam SA, Wang CC, Gardella CM, Sandison TG, Phipps WT, Hawes SE. Pregnancy complications associated with hepatitis C: data from a 2003–2005 Washington state birth cohort. Am J Obstet Gynecol. 2008;199(1):38 e1–9. Scholar
  10. 10.
    Puljic A, Salati J, Doss A, Caughey AB. Outcomes of pregnancies complicated by liver cirrhosis, portal hypertension, or esophageal varices. J Matern Fetal Neona. 2016;29(3):506–9. Scholar
  11. 11.
    Ceci O, Margiotta M, Marello F, Francavilla R, Loizzi P, Francavilla A, et al. Vertical transmission of hepatitis C virus in a cohort of 2,447 HIV-seronegative pregnant women: a 24-month prospective study. J Pediatr Gastroenterol Nutr. 2001;33(5):570–5.CrossRefPubMedGoogle Scholar
  12. 12.
    Mast EE, Hwang LY, Seto DS, Nolte FS, Nainan OV, Wurtzel H, et al. Risk factors for perinatal transmission of hepatitis C virus (HCV) and the natural history of HCV infection acquired in infancy. J Infect Dis. 2005;192(11):1880–9. Scholar
  13. 13.
    Shebl FM, El-Kamary SS, Saleh DA, Abdel-Hamid M, Mikhail N, Allam A, et al. Prospective cohort study of mother-to-infant infection and clearance of hepatitis C in rural Egyptian villages. J Med Virol. 2009;81(6):1024–31. Scholar
  14. 14.
    Jhaveri R, Hashem M, El-Kamary SS, Saleh DA, Sharaf S, El-Mougy F, et al. Hepatitis C virus (HCV) vertical transmission in 12-month-old infants born to HCV-infected women and assessment of maternal risk factors. Open Forum Infect Dis. 2015;2(2):ofv089. Scholar
  15. 15.
    Thomas DL, Villano SA, Riester KA, Hershow R, Mofenson LM, Landesman SH, et al. Perinatal transmission of hepatitis C virus from human immunodeficiency virus type 1-infected mothers. Women and infants transmission study. J Infect Dis. 1998;177(6):1480–8.CrossRefPubMedGoogle Scholar
  16. 16.
    Checa Cabot CA, Stoszek SK, Quarleri J, Losso MH, Ivalo S, Peixoto MF, et al. Mother-to-child transmission of hepatitis C virus (HCV) among HIV/HCV-coinfected women. J Pediatr Infect Dis Soc. 2013;2(2):126–35. Scholar
  17. 17.
    Jhaveri R, Swamy GK. Hepatitis C virus in pregnancy and early childhood: current understanding and knowledge deficits. J Pediatr Infect Dis Soc. 2014;3(Suppl 1):S13–8. Scholar
  18. 18.
    Padula D, Rodella A, Spandrio M, Rossini A, Cariani E. Spontaneous recovery from perinatal infection due to hepatitis C virus. Clin Infect Dis. 1999;28(1):141–2.CrossRefPubMedGoogle Scholar
  19. 19.
    European Paediatric Hepatitis C Virus Network. Three broad modalities in the natural history of vertically acquired hepatitis C virus infection. Clin Infect Dis. 2005;41(1):45–51.Google Scholar
  20. 20.
    Jonas MM. Children with hepatitis C. Hepatology. 2002;36(5 Suppl 1):S173–8. Scholar
  21. 21.
    Goodman ZD, Makhlouf HR, Liu L, Balistreri W, Gonzalez-Peralta RP, Haber B, et al. Pathology of chronic hepatitis C in children: liver biopsy findings in the Peds-C trial. Hepatology. 2008;47(3):836–43. Scholar
  22. 22.
    Gonzalez-Peralta RP, Langham MR Jr, Andres JM, Mohan P, Colombani PM, Alford MK, et al. Hepatocellular carcinoma in 2 young adolescents with chronic hepatitis C. J Pediatr Gastroenterol Nutr. 2009;48(5):630–5. Scholar
  23. 23.
    European Paediatric Hepatitis C Virus Network. A significant sex—but not elective cesarean section—effect on mother-to-child transmission of hepatitis C virus infection. J Infect Dis. 2005;192(11):1872–9.
  24. 24.
    European Paediatric Hepatitis C Virus Network. Effects of mode of delivery and infant feeding on the risk of mother-to-child transmission of hepatitis C virus. BJOG. 2001;108(4):371–7.CrossRefGoogle Scholar
  25. 25.
    Gibb DM, Goodall RL, Dunn DT, Healy M, Neave P, Cafferkey M, et al. Mother-to-child transmission of hepatitis C virus: evidence for preventable peripartum transmission. Lancet. 2000;356(9233):904–7.CrossRefPubMedGoogle Scholar
  26. 26.
    Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009;461(7262):399–401. Scholar
  27. 27.
    Ruiz-Extremera A, Munoz-Gamez JA, Salmeron-Ruiz MA, de Rueda PM, Quiles-Perez R, Gila-Medina A, et al. Genetic variation in interleukin 28B with respect to vertical transmission of hepatitis C virus and spontaneous clearance in HCV-infected children. Hepatology. 2011;53(6):1830–8. Scholar
  28. 28.
    Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O'Huigin C, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature. 2009;461(7265):798–801. Scholar
  29. 29.
    Hashem M, Jhaveri R, Saleh DA, Sharaf S, El-Mougy F, Abdelsalam L, et al. Spontaneous viral load decline and subsequent clearance of chronic hepatitis C virus in postpartum women correlates with favorable interleukin-28B gene allele. Clin Infect Dis. 2017;65(6):999–1005. Scholar
  30. 30.
    Dickover RE, Dillon M, Leung KM, Krogstad P, Plaeger S, Kwok S, et al. Early prognostic indicators in primary perinatal human immunodeficiency virus type 1 infection: importance of viral RNA and the timing of transmission on long-term outcome. J Infect Dis. 1998;178(2):375–87.CrossRefPubMedGoogle Scholar
  31. 31.
    Frederick T, Mascola L, Eller A, O'Neil L, Byers B. Progression of human immunodeficiency virus disease among infants and children infected perinatally with human immunodeficiency virus or through neonatal blood transfusion. Los Angeles County Pediatric AIDS Consortium and the Los Angeles County-University of Southern California Medical Center and the University of Southern California School of Medicine. Pediatr Infect Dis J. 1994;13(12):1091–7.CrossRefPubMedGoogle Scholar
  32. 32.
    Diaz C, Hanson C, Cooper ER, Read JS, Watson J, Mendez HA, et al. Disease progression in a cohort of infants with vertically acquired HIV infection observed from birth: the women and infants transmission study (WITS). J Acquir Immune Defic Syndr Hum Retrovirol. 1998;18(3):221–8.CrossRefPubMedGoogle Scholar
  33. 33.
    Connor EM, Sperling RS, Gelber R, Kiselev P, Scott G, O'Sullivan MJ, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group protocol 076 study group. N Engl J Med. 1994;331(18):1173–80. Scholar
  34. 34.
    Achievements in public health. Reduction in perinatal transmission of HIV infection—United States, 1985–2005. MMWR Morb Mortal Wkly Rep. 2006;55(21):592–7.Google Scholar
  35. 35.
    Stevens CE, Beasley RP, Tsui J, Lee WC. Vertical transmission of hepatitis B antigen in Taiwan. N Engl J Med. 1975;292(15):771–4. Scholar
  36. 36.
    Beasley RP, Hwang LY, Lee GC, Lan CC, Roan CH, Huang FY, et al. Prevention of perinatally transmitted hepatitis B virus infections with hepatitis B immune globulin and hepatitis B vaccine. Lancet. 1983;2(8359):1099–102.CrossRefPubMedGoogle Scholar
  37. 37.
    Schillie S, Walker T, Veselsky S, Crowley S, Dusek C, Lazaroff J, et al. Outcomes of infants born to women infected with hepatitis B. Pediatrics. 2015;135(5):e1141–7.
  38. 38.
    Xu WM, Cui YT, Wang L, Yang H, Liang ZQ, Li XM, et al. Lamivudine in late pregnancy to prevent perinatal transmission of hepatitis B virus infection: a multicentre, randomized, double-blind, placebo-controlled study. J Viral Hepat. 2009;16(2):94–103. Scholar
  39. 39.
    Celen MK, Mert D, Ay M, Dal T, Kaya S, Yildirim N, et al. Efficacy and safety of tenofovir disoproxil fumarate in pregnancy for the prevention of vertical transmission of HBV infection. World J Gastroenterol. 2013;19(48):9377–82. Scholar
  40. 40.
    Pan CQ, Duan Z, Dai E, Zhang S, Han G, Wang Y, et al. Tenofovir to prevent hepatitis B transmission in mothers with high viral load. N Engl J Med. 2016;374(24):2324–34. Scholar
  41. 41.
    Chen HL, Lee CN, Chang CH, Ni YH, Shyu MK, Chen SM, et al. Efficacy of maternal tenofovir disoproxil fumarate in interrupting mother-to-infant transmission of hepatitis B virus. Hepatology. 2015;62(2):375–86. Scholar
  42. 42.
    Terrault NA, Bzowej NH, Chang KM, Hwang JP, Jonas MM, Murad MH. AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2016;63(1):261–83. Scholar
  43. 43.
    Lawitz E, Poordad FF, Pang PS, Hyland RH, Ding X, Mo H, et al. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. Lancet. 2014;383(9916):515–23. Scholar
  44. 44.
    Wilson-Mitchell K, Rummens JA. Perinatal outcomes of uninsured immigrant, refugee and migrant mothers and newborns living in Toronto, Canada. Int J Environ Res Public Health. 2013;10(6):2198–213. Scholar
  45. 45.
    Wilson-Mitchell K. Increasing access to prenatal care: disease prevention and sound business practice. Health Care Women Int. 2014;35(2):120–6. Scholar
  46. 46.
    Ly KN, Jiles RB, Teshale EH, Foster MA, Pesano RL, Holmberg SD. Hepatitis C virus infection among reproductive-aged women and children in the United States, 2006 to 2014. Ann Intern Med. 2017;166(11):775–82. Scholar
  47. 47.
    Ly KN, Xing J, Klevens RM, Jiles RB, Ward JW, Holmberg SD. The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann Intern Med. 2012;156(4):271–8. Scholar
  48. 48.
    Aghemo A, Prati GM, Rumi MG, Soffredini R, D'Ambrosio R, Orsi E, et al. Sustained virological response prevents the development of insulin resistance in patients with chronic hepatitis C. Hepatology. 2012;56(5):1681–7. Scholar
  49. 49.
    Kowdley KV, Gordon SC, Reddy KR, Rossaro L, Bernstein DE, Lawitz E, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med. 2014;370(20):1879–88. Scholar
  50. 50.
    Yehia BR, Schranz AJ, Umscheid CA, Lo Re V III. The treatment cascade for chronic hepatitis C virus infection in the United States: a systematic review and meta-analysis. PLoS One. 2014;9(7):e101554. Scholar
  51. 51.
    Kuncio DE, Newbern EC, Johnson CC, Viner KM. Failure to test and identify perinatally infected children born to hepatitis C virus-infected women. Clin Infect Dis. 2016;62(8):980–5. Scholar
  52. 52.
    Davis GL, Alter MJ, El-Serag H, Poynard T, Jennings LW. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology. 2010;138(2):513–21, 21 e1–6. Scholar
  53. 53.
    Asrani SK, Davis GL. Impact of birth cohort screening for hepatitis C. Curr Gastroenterol Rep. 2014;16(4):381. Scholar
  54. 54.
    Bonner JE, Barritt AS 4th, Fried MW, Evon DM. Time to rethink antiviral treatment for hepatitis C in patients with coexisting mental health/substance abuse issues. Dig Dis Sci. 2012;57(6):1469–74. Scholar
  55. 55.
    Chahal HS, Marseille EA, Tice JA, Pearson SD, Ollendorf DA, Fox RK, et al. Cost-effectiveness of early treatment of hepatitis C virus genotype 1 by stage of liver fibrosis in a US treatment-naive population. JAMA Intern Med. 2016;176(1):65–73. Scholar
  56. 56.
    Nuno Solinis R, Arratibel Ugarte P, Rojo A, Sanchez Gonzalez Y. Value of treating all stages of chronic hepatitis C: a comprehensive review of clinical and economic evidence. Infect Dis Ther. 2016;5(4):491–508. Scholar
  57. 57.
    McAdam-Marx C, McGarry LJ, Hane CA, Biskupiak J, Deniz B, Brixner DI. All-cause and incremental per patient per year cost associated with chronic hepatitis C virus and associated liver complications in the United States: a managed care perspective. J Manag Care Pharm. 2011;17(7):531–46. Scholar
  58. 58.
    Gordon SC, Pockros PJ, Terrault NA, Hoop RS, Buikema A, Nerenz D, et al. Impact of disease severity on healthcare costs in patients with chronic hepatitis C (CHC) virus infection. Hepatology. 2012;56(5):1651–60. Scholar
  59. 59.
    Reau NS, Jensen DM. Sticker shock and the price of new therapies for hepatitis C: is it worth it? Hepatology. 2014;59(4):1246–9. Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Division of Gastroenterology, Department of Medicine, UNC School of MedicineChapel HillUSA
  2. 2.Division of Infectious Diseases, Department of Pediatrics UNC School of MedicineChapel HillUSA

Personalised recommendations